Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.94)
# 1,653
Out of 5,014 analysts
141
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $15.05 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $36.94 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $563.86 | +50.75% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.97 | +813.71% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.62 | +3,603.70% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.87 | +213.59% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $8.94 | +280.31% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $150.97 | +116.60% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $4.88 | +514.75% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $29.44 | +1,829.35% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $421.15 | -33.28% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.85 | +180.70% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.51 | +6,390.07% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $294.62 | +0.13% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $118.25 | -27.27% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $35.75 | +34.27% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.26 | +263.20% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $42.60 | +69.01% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.51 | +231.13% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $85.38 | +17.12% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $210.13 | -4.34% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $64.48 | +31.82% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $11.53 | +177.54% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $23.38 | +828.14% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $31.83 | +50.80% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $19.75 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $450.68 | -65.83% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $54.69 | +112.10% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $5.23 | +1,926.77% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $24.47 | +14.43% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $187.92 | -56.36% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $448.93 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.51 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.05
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.94
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $563.86
Upside: +50.75%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.97
Upside: +813.71%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.62
Upside: +3,603.70%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.87
Upside: +213.59%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $8.94
Upside: +280.31%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $150.97
Upside: +116.60%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $4.88
Upside: +514.75%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $29.44
Upside: +1,829.35%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $421.15
Upside: -33.28%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $2.85
Upside: +180.70%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.51
Upside: +6,390.07%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $294.62
Upside: +0.13%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $118.25
Upside: -27.27%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $35.75
Upside: +34.27%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $8.26
Upside: +263.20%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $42.60
Upside: +69.01%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.51
Upside: +231.13%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $85.38
Upside: +17.12%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $210.13
Upside: -4.34%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $64.48
Upside: +31.82%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $11.53
Upside: +177.54%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $23.38
Upside: +828.14%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $31.83
Upside: +50.80%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $19.75
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $450.68
Upside: -65.83%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $54.69
Upside: +112.10%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $5.23
Upside: +1,926.77%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $24.47
Upside: +14.43%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $187.92
Upside: -56.36%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $448.93
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.51
Upside: -